stockportfolio.pro
Amneal Pharmaceuticals, Inc. Revenue 2016–2025
Amneal Pharmaceuticals, Inc. (AMRX) annual revenue by fiscal year, computed from SEC filings. Compound growth +12.8%/yr over 9 years.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $3.02B | +8.0% |
| FY 2024 | $2.79B | +16.7% |
| FY 2023 | $2.39B | +8.2% |
| FY 2022 | $2.21B | +5.7% |
| FY 2021 | $2.09B | +5.1% |
| FY 2020 | $1.99B | +22.5% |
| FY 2019 | $1.63B | -2.2% |
| FY 2018 | $1.66B | +60.9% |
| FY 2017 | $1.03B | +1.5% |
| FY 2016 | $1.02B | — |
Source: Amneal Pharmaceuticals, Inc. SEC filings — income statement (10-K). Refreshed nightly.
See the full picture for Amneal Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmneal Pharmaceuticals, Inc. — frequently asked questions
What is Amneal Pharmaceuticals, Inc.'s revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.02B for fiscal year 2025, per its SEC filings.
How has Amneal Pharmaceuticals, Inc.'s revenue changed over time?
Between fiscal 2016 and 2025, AMRX's revenue grew at roughly 12.8% per year (compound annual rate), from $1.02B to $3.02B.
Where does this data come from?
Figures are computed from Amneal Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.